JAK inhibitors plus standard of care vs placebo or usual careSerious adverse events · hospitalised people with confirmed SARS‐CoV‐2 infection1 finding from 1 reviewJanus kinase inhibitors for the treatment of COVID‐19 2022 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 2901 participantsModerate
Summary of findings table ‐ Corticosteroids plus standard care vs placebo or usual careSerious adverse events ( · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐191 finding from 1 reviewSystemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 678 participantsVery low